The Bahjat Laboratory is interested in understanding the signals that regulate the expansion and function of CD8+ T cells, and why seemingly healthy, normal T cells would be rendered incapable of killing their intended target. The laboratory utilizes models of microbial infection to elicit a robust, well-characterized T cell response.
Christopher Dubay, Ph.D.
Program manager, Biomedical Informatics
With his extensive background in data management and bioinformatic analysis, Dr. Dubay works closely with our investigators and other health system IT professionals to strengthen our research efforts with bioinformatics support.
Bernard A. Fox, Ph.D.
Chief, Laboratory of Molecular and Tumor Immunology
The Laboratory of Molecular and Tumor Immunology hypothesizes that a primary reason for the failure of past tumor vaccine strategies is that the magnitude of the antitumor immune response is insufficient to mediate tumor regression. One answer to this is to create a lymphopenic host, reconstitute that host with lymphocytes and then inoculate with a tumor vaccine. Read more.
John E. Godwin, M.D., M.S.
Medical oncologist/ hematologist
Dr. Godwin is a medical oncologist and hematologist specializing in the treatment of leukemia, lymphoma and blood coagulation. He has conceived, designed and led innovative clinical trials in leukemia and lymphoma for Southwest Oncology Group. Dr. Godwin has served on various panels for the NIH-NCI and was a member of the NCI Leukemia Steering Committee before joining the Earle A. Chiles Research Institute. Read more.
Michael J. Gough, Ph.D.
Principal investigator, Laboratory of Integrated Therapies
The Integrated Therapies Laboratory is a collaborative research effort between Dr. Gough and Marka R. Crittenden, M.D., Ph.D. It encompasses their overlapping research interest into the ability of cytotoxic therapy to provide large-scale cancer cell death in vivo, while modifying the profile of immune cells within the tumor. Read more.
Hong-Ming Hu, Ph.D.
Chief, Laboratory of Cancer Immunobiology
The long-term goal of the Laboratory of Cancer Immunobiology is to understand how the immune system senses tumor cells and develop effective cancer vaccines and immunotherapy strategies. Read more.
Rom S. Leidner, M.D.
Dr. Leidner is a medical oncologist specializing in the treatment of patients with oral, head, neck and thoracic cancers. He is also a clinical investigator at the Earle A. Chiles Research Institute focusing on immunotherapy for head and neck cancers in collaboration with Providence Oral, Head and Neck Cancer Program
. Read more.
William L. Redmond, Ph.D.
Principal investigator, Laboratory of Cancer Immunotherapy
The goal of the Laboratory of Cancer Immunotherapy is to determine the molecular mechanisms by which tumors induce immune suppression. Ultimately, understanding how tumors escape destruction by the immune system will guide the development of novel anti-tumor therapies. Read more.
Rachel E. Sanborn, M.D.
Co-director, Thoracic Oncology Program
Dr. Sanborn is a medical oncologist specializing in the treatment of patients with lung cancer. She is also co-director of Providence Thoracic Oncology Program
at Providence Cancer Center and a clinical investigator at the Earle A. Chiles Research Institute. Read more about Dr. Sanborn’s clinical practice
and lung cancer research
Andrew D. Weinberg, Ph.D.
Chief, Laboratory of Basic Immunology
The main focus of the Laboratory of Basic Immunology is to understand T cell activation during disease states. We have explored ways to manipulate the fate of antigen-specific T cells to enhance tumor-specific memory in hosts with cancer or down-regulate antigen-specific responses in autoimmune disease. Read more.
Jennifer Wilk, D.V.M., DACLAM
Director, Cancer Research Animal Division
Under the direction of Dr. Wilk and her staff, our research is enhanced through the provision of healthier animal models and collaboration in clinical protocol development. Dr. Wilk provides guidance for laboratory staff in regards to protocol development and project support.